The robustanticancer activity of 35 resulted in adose- and time-dependent effect on the proliferation of KARPAS422cells, a DLBCL cell line holding the Y641N EZH2 gain-of-function mutation.Subcutaneous administration of 35 in the mouse xenograftmodel of KARPAS422 demonstrated good tolerability with no apparentside effects. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.